Onfasprodil

Add links
Source: Wikipedia, the free encyclopedia.
Onfasprodil
Clinical data
Other namesMIJ821
Drug classNMDA receptor modulator
Legal status
Legal status
  • Investigational
Identifiers
  • 6-{(1S)-2-[(3aR,5R,6aS)-5-(2-Fluorophenoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1-hydroxyethyl}-3-pyridinol
JSmol)
  • O([C@@H]1C[C@@]2([C@](C1)(CN(C[C@H](O)C3=CC=C(O)C=N3)C2)[H])[H])C4=C(F)C=CC=C4
  • InChI=1S/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/m0/s1
  • Key:NEFQLCKWVRZEJA-ZDXGLAPJSA-N

Onfasprodil (MIJ821) is a drug delivered via

negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.[1][2]

References

  1. PMID 37817426
    .
  2. S2CID 265360324
    .


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Onfasprodil&oldid=1202165043"